FDA approves new diabetes drug

Julia Rommelfanger

August 02, 2000

Wed, 02 Aug 2000 18:06:47

Princeton, NJ - The FDA has approved Bristol-Myers Squibb ' s new type 2 diabetes treatment Glucovance?, which combines the oral antidiabetic agents glyburide and metformin into one pill, the company announced.

Glucovane is indicated as initial drug therapy for type 2 diabetes, along with diet and exercise, and as second-line therapy in patients whose glucose levels cannot be adequately controlled with diet, exercise, and metformin or a sulfonylurea.

The drug will be available in three dosing strengths, 1.25 mg glyburide/250 mg metformin, 2.5 mg/500 mg, and 5 mg/500 mg tablets.

The company warned that patients taking heart failure medications, drink excessive alcohol and those with kidney and liver problems should not take Glucovance.

Bristol-Myers Squibb has been under recent scrutiny for withdrawing a New Drug Application for its heavily promoted hypertension and heart failure drug omapatrilat in April after the FDA expressed concerns about the drug's side effects, as reported by heart wire .

Related link

1. heart wire / Apr 19, 2000 /


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.